MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 2, 2012, Pages 224-226

  Phan Ba, Rémy ^a   Lommers, Emilie ^a   Tshibanda, Luaba ^a   Calay, Philippe ^a   Dubois, Bernard ^a   Moonen, Gustave ^a   Clifford, David ^b   Belachew, Shibeshih ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE COURSE; DRUG BLOOD LEVEL; EARLY DIAGNOSIS; FOLLOW UP; HEADACHE; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; JC VIRUS; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PLEOCYTOSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; BRAIN; DISEASE PROGRESSION; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OLIGODENDROGLIA; POLYMERASE CHAIN REACTION;

EID: 84855575065     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2011-300511     Document Type: Article

References (14)

1. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-82. (Pubitemid 29219261)
2. Fischer JS, Rudick RA, Cutter GR, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244-50. (Pubitemid 29405620)
3. Nieuwenhuis MM, Van Tongeren H, Sorensen PS, et al. The six spot step test: a new measurement for walking ability in multiple sclerosis. Mult Scler 2006;12:495-500. (Pubitemid 44132591)
4. Phan-Ba R, Pace A, Calay P, et al. Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis. Neurorehabil Neural Repair 2011;25:672-9.
5. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295-303.
6. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
7. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-46.
8. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011;10:745-58.
9. Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011;76:1697-704.
10. Johnson T, Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol 2011;24:284-90.
11. Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009;72:1458-64.
12. Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009;361:1075-80.
13. Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009;361:1081-7.
14. Vennegoor A, Wattjes MP, van Munster ET, et al. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology 2011;76:574-6.